Senti Biosciences is trading at $0.35 (6.2% down) as the stock faces ongoing technical and liquidity-driven pressure.
- The stock has slid steadily over the past week, diverging from a generally rising biotech sector.
- No new company-specific news, earnings, or regulatory developments have been reported to explain the downward move.
- Traders appear to be reacting to prior weakness and broader risk-off sentiment impacting smaller biotech names amid thin liquidity.